Behçet’s disease uveitis: is there a need for new emerging drugs?

References

• Behçet H. Über rezidivierende aphthöse durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr. 1937;105:1152–1157.
   Google Scholar
• Keino H, Okada AA. Behçet’s disease: global epidemiology of an Old Silk Road disease. Br J Ophthalmol. 2007;91(12):1573–1574.
   PubMed Web of Science ®Google Scholar
• Azizlerli G, Köse AA, Sarica R, et al. Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42(10):803–806.
   PubMed Web of Science ®Google Scholar
• Gül A. Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4(1):81–83.
   PubMedGoogle Scholar
• Direskeneli H. Autoimmunity vs autoinflammation in Behçet’s disease: do we oversimplify a complex disorder? Rheumatology. 2006;45(12):1461–1465.
   PubMed Web of Science ®Google Scholar
• Khairallah M, Accorinti M, Muccioli C, et al. Epidemiology of Behçet disease. Ocul Immunol Inflamm. 2012;20(5):324–325.
   PubMed Web of Science ®Google Scholar
• Yalçındağ FN, Özdal PC, Özyazgan Y, et al. Demographic and clinical characteristics of uveitis in Turkey: the first national registry report. Ocul Immunol Inflamm. 2018;26:17–26.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–380.
   PubMed Web of Science ®Google Scholar
• PÇ Ö, Ortaç S, Taskintuna I, et al. Posterior segment involvement in ocular Behçet’s disease. Eur J Ophthalmol. 2002;12:424–431.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I. Behçet’s Uveitis. Middle East Afr J Ophthalmol. 2009;16:219–224.
   PubMedGoogle Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82(1):60–76.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Venerito V, Sota J, et al. Epidemiological profile of non-infectious uveitis from the rheumatologist’s perspective: a survey from two tertiary referral centres in Italy. Clin Exp Rheumatol. 2018;36(6 Suppl 115):68–73.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Stanford M, et al. An algorithm for the diagnosis of Behçet disease uveitis in adults. Ocul Immunol Inflamm. 2020 Apr;14:1–10.
   Google Scholar
• Zierhut M, Abu El-Asrar AM, Bodaghi B, et al. Therapy of ocular Behçet disease. Ocul Immunol Inflamm. 2014;22(1):64–76.
   PubMed Web of Science ®Google Scholar
• Onal S, Tugal-Tutkun I. Behçet Disease. In: Biswas J, PD M, editors. Uveitis: an update. India: Springer; 2016. p. 17–31.
   Google Scholar
• Hatemi G, Christensen R, Bang D, et al. update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77:808–818.
   PubMed Web of Science ®Google Scholar
• Cingu AK, Onal S, Urgancioglu M, et al. Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm. 2012;20(6):423–428.
   PubMed Web of Science ®Google Scholar
• Kitaichi N, Miyazaki A, Iwata D, et al. Ocular features of Behcet’s disease: an international collaborative study. Br J Ophthalmol. 2007;91(12):1579–1582.
   PubMed Web of Science ®Google Scholar
• Taylor SR, Singh J, Menezo V, et al. Behçet disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol. 2011;152(6):1059–1066.
   PubMed Web of Science ®Google Scholar
• Yang P, Fang W, Meng Q, et al. Clinical features of chinese patients with Behçet’s disease. Ophthalmology. 2008;115:312–318.e4.
   Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.
   PubMed Web of Science ®Google Scholar
• Yalçindag N, Köse HC. Comparison of the treatment results for Behçet uveitis in patients treated with infliximab and interferon. Ocul Immunol Inflamm. 2020;28(2):305–314.
   PubMed Web of Science ®Google Scholar
• Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther. 2007;23(4):395–401.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Araz B, Cagatay A. CMV retinitis after intravitreal triamcinolone acetonide injection in a patient with Behçet’s uveitis. Int Ophthalmol. 2010;30(5):591–593.
   PubMedGoogle Scholar
• Oh EK, Lee EK, Yu HG. Long-term results of fluocinolone acetonide intravitreal implant in Behçet intractable posterior uveitis. Can J Ophthalmol. 2014;49(3):273–278.
   PubMed Web of Science ®Google Scholar
• Yalcinbayir O, Caliskan E, Ucan Gunduz G, et al. Efficacy of dexamethasone implants in uveitic macular edema in cases with Behçet disease. Ophthalmologica. 2019;241(4):190–194.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Emmi G, Lopalco G, et al. Intravitreal dexamethasone implant as an adjunct weapon for severe and refractory uveitis in Behçet’s disease. Isr Med Assoc J. 2017;19:415–419.
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322(5):281–285.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769–774.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet’s disease. Arthritis Care Res (Hoboken). 2010;62(12):1733–1738.
   PubMed Web of Science ®Google Scholar
• van Daele PL, Kappen JH, van Hagen PM, et al. Managing Behçet’s disease: an update on current and emerging treatment options. Ther Clin Risk Manag. 2009;5:385–390.
   PubMedGoogle Scholar
• Alexoudi I, Kapsimali V, Vaiopoulos A, et al. Evaluation of current therapeutic strategies in Behçet’s disease. Clin Rheumatol. 2011;30(2):157–163.
   PubMed Web of Science ®Google Scholar
• Bettiol A, Hatemi G, Vannozzi L, et al. Treating the different phenotypes of Behçet’s syndrome. Front Immunol. 2019;10:2830.
   PubMed Web of Science ®Google Scholar
• Ksiaa I, Abroug N, Kechida M, et al. Eye and Behçet’s disease. J Fr Ophthalmol. 2019;42(4):e133–e146.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Shahram F, et al. Methotrexate in ocular manifestations of Behcet’s disease: a longitudinal study up to 15 years. Int J Rheum Dis. 2013;16(5):568–577.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: A Randomized Clinical Trial. JAMA. 2019;322(10):936–945.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, et al. Effectiveness of cyclosporin therapy for Behçet’s disease. Arthritis Rheum. 1985;28(6):671–679.
   PubMedGoogle Scholar
• Masuda K, Urayama A, Kogure M, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet. 1989;333(8647):1093–1096.
   Google Scholar
• BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet’s syndrome. Transplant Proc. 1988;20:136–143.
   PubMed Web of Science ®Google Scholar
• Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol. 1992;76(4):241–243.
   PubMed Web of Science ®Google Scholar
• Özdal PÇ, Ortaç S, Taskıntuna I, et al. Long-term therapy with low dose cyclosporin-A in ocular Behçet’s disease. Doc Ophthalmol. 2002;105(3):301–312.
   PubMedGoogle Scholar
• Akman-Demir G, Ayranci O, Kurtuncu M, et al. Cyclosporine for Behçet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26(Suppl 50):84–90.
   Google Scholar
• Mochizuki M, Masuda K, Sakane T, et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behcet’s disease: japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc. 1991;23:3343–3346.
   PubMed Web of Science ®Google Scholar
• Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999 Apr;106(4):723–728.
   PubMed Web of Science ®Google Scholar
• Kazokoglu H, Saatci O, Cuhadaroglu H, et al. Long-term effects of cyclophosphamide and colchicine treatment in Behcet’s disease. Ann Ophthalmol. 1991;23:148–151.
   PubMedGoogle Scholar
• Gurcan M, Esatoglu SN, Hamuryudan V, et al. Long term follow-up of Behçet’s syndrome patients treated with cyclophosphamide [published online ahead of print, 2019 Dec 16]. Rheumatology (Oxford). 2019;kez598. 10.1093/rheumatology/kez598.
   Google Scholar
• Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet’s disease. Br J Ophthalmol. 1990;74(6):353–357.
   PubMed Web of Science ®Google Scholar
• Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behçet’s disease. Ocul Immunol Inflamm. 2001;9(4):219–229.
   PubMed Web of Science ®Google Scholar
• Onal S, Savar F, Akman M, et al. Vision- and health-related quality of life in patients with Behçet uveitis. Arch Ophthalmol. 2010;128(10):1265–1271.
   PubMedGoogle Scholar
• Sakai T, Watanabe H, Kuroyanagi K, et al. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis. Br J Ophthalmol. 2013;97(3):338–342.
   PubMed Web of Science ®Google Scholar
• Ozguler Y, Leccese P, Christensen R, et al. Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology (Oxford). 2018;57:2200–2212.
   PubMed Web of Science ®Google Scholar
• Kötter I, Günaydin I, Zierhut M, et al. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320–335.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467–471.
   PubMed Web of Science ®Google Scholar
• Kötter I, Vonthein R, Schoenfisch B, et al. AB0545 Interferon alpha2a versus cyclosporin A for the treatment of severe ocular Behcet’s disease – A prospective, randomised, single blind, national multicenter trial (INCYTOB). Ann Rheum Dis. 2016;75(Suppl 2):1091.
   Google Scholar
• Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423–431.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146(837–44.e1):837–844.e1.
   PubMedGoogle Scholar
• Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 2010;62:2796–2805.
   PubMed Web of Science ®Google Scholar
• Diwo E, Gueudry J, Saadoun D, et al. Long-term Efficacy of interferon in severe uveitis associated with Behçet disease. Ocul Immunol Inflamm. 2017;25(1): 76–84. .
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692–1695.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011;129:288–294.
   PubMed Web of Science ®Google Scholar
• Grace MJ, Cutler D. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother. 2004;15:287–297.
   PubMedGoogle Scholar
• Lightman S, Taylor SR, Bunce C, et al. Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet’s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis. 2015;74:1138–1144.
   PubMed Web of Science ®Google Scholar
• Celiker H, Kazokoglu H, Direskeneli H. Long-term efficacy of pegylated interferon alpha-2b in Behçet’s uveitis: A small case series. Ocul Immunol Inflamm. 2019;27:15–22.
   PubMed Web of Science ®Google Scholar
• Bielefeld P, Devilliers H, Deschasse C, et al. Potential of pegylated interferon alpha-2a in Behçet uveitis: a report of five cases. Ocul Immunol Inflamm. 2016;24:599–602.
   PubMed Web of Science ®Google Scholar
• Onal S, Tugal-Tutkun I. Re: Levy-Clarke et al.: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders (Ophthalmology 2014;121:785-96). Ophthalmology. 2014;121:e57–8.
   Web of Science ®Google Scholar
• Keskin Y, Seyahi E, Poyraz C, et al. Interferon alfa-associated depression in patients with Behçet’s syndrome: a prospective controlled study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S175.
   PubMed Web of Science ®Google Scholar
• Hu Y, Huang Z, Yang S, et al. Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Behcets’ disease-associated uveitis: a systematic review and meta-analysis. Front Pharmacol. 2020;11:941.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;12:785–796.
   Google Scholar
• Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort series. BMJ. 2009;339:b2480.
   PubMedGoogle Scholar
• Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53:2223–2231.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet. 2001;358(9278):295–296.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52:2478–2484.
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–1368.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140:404–406.
   PubMed Web of Science ®Google Scholar
• Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61–70.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behcet’s disease receiving infliximab treatment. Br J Ophthalmol. 2011;95:205–208.
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146:845–50.e1.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94:284–288.
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet’s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50:593–597.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology. 2014;121:1877–1884.
   PubMed Web of Science ®Google Scholar
• Kaburaki T, Namba K, Sonoda KH, et al. Behçet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120–130.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245–1250.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, et al. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet’s disease. Eye (Lond). 2014;28:1100–1106.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, et al. Efficacy of infliximab for early remission induction in refractory uveoretinitis associated with Behçet disease: a 2-year follow-up study. Ocul Immunol Inflamm. 2017;25:46–51.
   PubMed Web of Science ®Google Scholar
• Guzelant G, Ucar D, Esatoglu SN, et al. Infliximab for uveitis of Behçet’s syndrome: a trend for earlier initiation. Clin Exp Rheumatol. 2017;35(Suppl 108):86–89.
   PubMedGoogle Scholar
• Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br J Ophthalmol. 2011;95:549–552.
   PubMed Web of Science ®Google Scholar
• Ueda S, Akahoshi M, Takeda A, et al. Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet’s disease. Eur J Rheumatol. 2018;5:9–15.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Vitale A, et al. Ten-year retention rate of infliximab in patients with Behçet’s disease-related uveitis. Ocul Immunol Inflamm. 2019;27:34–39.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Arida A, Ladas DS, et al. Induction of ocular Behçet’s disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years. Clin Exp Rheumatol. 2019;37(Suppl 121):137–141.
   PubMedGoogle Scholar
• Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Behçet’s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol. 2017;69:2380–2385.
   PubMed Web of Science ®Google Scholar
• Ohno S, Umebayashi I, Matsukawa M, et al. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther. 2019;21(1):2. Published 2019 Jan 5.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–943.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–1192.
   PubMed Web of Science ®Google Scholar
• Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Behcet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32:S58—62.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36:183–189.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease: national multicenter study of 177 cases. Arthritis Rheumatol. 2019;71:2081–2089.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Vitale A, et al. Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2018;102:637–641.
   PubMed Web of Science ®Google Scholar
• Bitossi A, Bettiol A, Silvestri E, et al. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: A multicenter retrospective study. Mediators Inflamm. 2019;2019:1623847.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125:1075–1087.
   PubMed Web of Science ®Google Scholar
• Chu DS, Johnson SJ, Mallya UG, et al. Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect. 2013 Nov 6;3(1):64.
   PubMedGoogle Scholar
• Rice JB, White AG, Scarpati LM, et al. The burden of non-infectious intraocular inflammatory eye diseases: a systematic literature review. Curr Med Res Opin. 2018;34(12):2095–2103.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Skup M, Tundia N, et al. Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmol. 2016;94(5):e331–9.
   PubMed Web of Science ®Google Scholar
• McNally TW, Damato EM, Murray PI, et al. An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review. Orphanet J Rare Dis. 2017 Jul 17;12(1):130.
   PubMedGoogle Scholar
• Sut N, Seyahi E, Yurdakul S, et al. A cost analysis of Behcet’s syndrome in Turkey. Rheumatology (Oxford). 2007;46(4):678–682.
   PubMed Web of Science ®Google Scholar
• Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s Disease [published correction appears in Ophthalmology. 2019 Jan;126(1):177]. Ophthalmology. 2018;125(9):1444–1451.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet’s disease: A comprehensive review. J Autoimmun. 2015;64:137–148.
   PubMed Web of Science ®Google Scholar
• Leccese P, Alpsoy E. Behçet’s Disease: an overview of etiopathogenesis. Front Immunol. 2019 10;10:1067. Published 2019 May 10.
   PubMed Web of Science ®Google Scholar
• Albayrak O, Oray M, Can F, et al. Effect of interferon alfa-2a treatment on adaptive and innate immune systems in patients with Behçet disease uveitis. Invest Ophthalmol Vis Sci. 2019;60(1):52–63.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab. Clin Rheumatol. 2018;37(6):1715–1720.
   PubMed Web of Science ®Google Scholar
• Sugita S, Yamada Y, Kaneko S, et al. Induction of regulatory T cells by infliximab in Behcet’s disease. Invest Ophthalmol Vis Sci. 2011;52(1):476–484.
   PubMed Web of Science ®Google Scholar
• Kirectepe Aydin A, Özgüler Y, Uçar D, et al. Peripheral blood mononuclear cell proteome profile in Behçet’s syndrome. Rheumatol Int. 2020;40(1):65–74.
   PubMed Web of Science ®Google Scholar
• Liang A, Qin W, Zhang M, et al. Profiling tear proteomes of patients with unilateral relapsed Behcet’s disease-associated uveitis using data-independent acquisition proteomics. PeerJ. 2020;8:e9250. Published 2020 Jun 19.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Ozdal PC, Oray M, et al. Review for Diagnostics of the Year: multimodal imaging in Behçet uveitis. Ocul Immunol Inflamm. 2017;25(1):7–19.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Cingü K, Kir N, et al. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246(8):1169–1177.
   PubMed Web of Science ®Google Scholar
• Keino H. Evaluation of disease activity in uveoretinitis associated with Behçet’s disease [published online ahead of print, 2020 Jul 29]. Immunol Med. 2020;1–12. DOI:10.1080/25785826.2020.1800244
   PubMedGoogle Scholar
• Tugal-Tutkun I, Herbort CP, Khairallah M. Angiography Scoring for uveitis working group (ASUWOG). Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30:539–553.
   PubMedGoogle Scholar
• Kang HM, Lee SC. Long-term progression of retinal vasculitis in Behçet patients using a fluorescein angiography scoring system. Graefes Arch Clin Exp Ophthalmol. 2014;252(6):1001–1008.
   PubMed Web of Science ®Google Scholar
• Shirahama S, Kaburaki T, Matsuda J, et al. The relationship between fluorescein angiography leakage after infliximab therapy and relapse of ocular inflammatory attacks in ocular Behçet’s disease patients. Ocul Immunol Inflamm 2020;28(8):1166–1170.
   Google Scholar
• Onal S, Uludag G, Oray M, et al. Quantitative analysis of structural alterations in the choroid of patients with active Behçet uveitis. Retina. 2018;38(4):828–840.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Harimoto K, Taguchi M, et al. Reconstitution of disrupted photoreceptor layer in uveitis associated with Behçet’s disease by infliximab treatment. BMC Ophthalmol. 2015;15(1):177.
   PubMedGoogle Scholar
• Khairallah M, Abroug N, Khochtali S, et al. Optical coherence tomography angiography in patients with Behçet uveitis. Retina. 2017;37(9):1678–1691.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease. Ocul Immunol Inflamm. 2019;27(1):58–63.
   PubMed Web of Science ®Google Scholar
• Tosi GM, Sota J, Vitale A, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019;37:680–683.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab pegol treatment in Behcet’s disease with different organ involvement: A multicenter retrospective observational study. Mod Rheumatol. 2017;27(6):1031–1035.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Rapid loss of efficacy of biosimilar infliximab in three patients with Behcet’s disease after switching from infliximab originator. Eur J Rheumatol. 2017;4(4):288–290.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Venerito V, Cantarini L, et al. Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behcet’s disease. Intern Emerg Med. 2019;14(5):719–722.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. The role of biosimilars in uveitis: long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors. Front Pharmacol. 2019;10:1468.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Lopalco G, et al. Interleukin-1 inhibition in Behçet’s disease. Isr Med Assoc J. 2016;18(3–4):171–176.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Squatrito D, et al. Long-term efficacy and safety of anakinra in a patient with Behçet’s disease and concomitant tuberculosis infection. Int J Dermatol. 2017;56(2):218–220.
   PubMed Web of Science ®Google Scholar
• Gül A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin- 1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563–566.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Kadayifcilar S, Khairallah M, et al. Safety and efficacy of gevokizumab in patients with Behçet’s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm. 2017;25(1):62–70.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with Behçet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023–1033.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34:1293–1301.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Caso F, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case series. Dermatology. 2014;228(3):211–214.
   PubMed Web of Science ®Google Scholar
• Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281–1286.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1): 191–197. .
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Behçet’s disease. Ocul Immunol Inflamm. 2020;28(2):298–304.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) Outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80.
   PubMed Web of Science ®Google Scholar
• Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85–94.
   PubMed Web of Science ®Google Scholar
• Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the treatment of Behçet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy. Ocul Immunol Inflamm. 2018;26(7):1005–1014.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57(5):856–864.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab. Clin Rheumatol. 2015;34(6):1141–1143.
   PubMed Web of Science ®Google Scholar
• Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology. 2019;126(3):428–437.
   PubMed Web of Science ®Google Scholar
• Sota J, Rigante D, Lopalco G, et al. Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatol Int. 2018;38(1):25–35.
   PubMed Web of Science ®Google Scholar
• Dick A, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–787.
   PubMed Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939–948.
   PubMed Web of Science ®Google Scholar
• Fagni F, Bettiol A, Talarico R, et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study. Ann Rheum Dis. 2020;79(8):1098–1104.
   PubMed Web of Science ®Google Scholar
• Dincses E, Yurttas B, Esatoglu SN, et al. Secukinumab induced Behçet’s syndrome: a report of two cases. Oxf Med Case Reports. 2019;2019(5):omz041.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246–252.
   PubMed Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet’s disease. Ocul Immunol Inflamm. 2007;15(2):63–70.
   PubMed Web of Science ®Google Scholar
• Wroblewski K, Sen HN, Yeh S, et al. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol. 2011;46(4):322–328.
   PubMed Web of Science ®Google Scholar
• Lockwood CM, Hale G, Waldmann H, et al. Remission induction in Behcet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH-1H. Rheumatology (Oxford). 2003;42(12):1539–1544.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Smith RM, Chow YW, et al. Alemtuzumab as remission induction therapy in behçet disease: a 20-year experience. J Rheumatol. 2015;42(10):1906–1913.
   PubMed Web of Science ®Google Scholar
• Mirouse A, Barete S, Desbois AC, et al. Long-term outcome of ustekinumab therapy for Behçet’s disease. Arthritis Rheumatol. 2019;71(10):1727–1732.
   PubMed Web of Science ®Google Scholar
• Maciel ML, Novello M, Neves FS. Short-term efficacy of abatacept in the treatment of refractory ocular and cutaneous Behçet’s disease. Rheumatol Adv Pract. 2017;1(1):rkx004.
   PubMedGoogle Scholar
• Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209–217.
   PubMed Web of Science ®Google Scholar
• Pleyer U, Algharably EA, Feist E, et al. Small molecules as therapy for uveitis: a selected perspective of new and developing agents. Expert Opin Pharmacother. 2017;18(13):1311–1323.
   PubMed Web of Science ®Google Scholar
• Liu J, Hou Y, Sun L, et al. A pilot study of tofacitinib for refractory Behçet’s syndrome. Ann Rheum Dis. 2020;79(11):1517–1520.
   Web of Science ®Google Scholar
• Paley MA, Karacal H, Rao PK, et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2018;13:53–55.
   PubMedGoogle Scholar
• Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2019;27(8):1232–1234.
   PubMed Web of Science ®Google Scholar
• Takeno M. Positioning of apremilast in treatment of Behçet’s disease. Mod Rheumatol. 2020;30(2):219–224.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome–a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–1518.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of apremilast for oral ulcers in Behcet’s syndrome. N Engl J Med. 2019;381(20):1918–1928.
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol. 2012;154(3):534–541.
   PubMed Web of Science ®Google Scholar
• Hamza MME, Macky TA, Sidky MK, et al. Intravitreal infliximab in refractory uveitis in Behcet’s disease: A safety and efficacy clinical study. Retina. 2016;36(12):2399–2408.
   PubMed Web of Science ®Google Scholar
• Kheir WJ, Mehanna C-J, Abdul Fattah M, et al. Intravitreal Adalimumab for the control of breakthrough intraocular inflammation. Ocul Immunol Inflamm. 2018;26(8):1206–1211.
   PubMed Web of Science ®Google Scholar
• Bae JH, Lee SC. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease. Retina. 2012;32(7):1395–1402.
   PubMed Web of Science ®Google Scholar
• Khalil HE, El Gendy HA, Youssef HA, et al. The Effectiveness of Intraocular Methotrexate in the Treatment of Posterior Uveitis in Behçet’s Disease Patients Compared to Retrobulbar Steroids Injection. J Ophthalmol. 2016;2016:1678495.
   PubMed Web of Science ®Google Scholar
• Merrill PT, Clark WL, Banker AS, et al. Sirolimus study assessing double-masked uveitis treatment (SAKURA) study group. efficacy and safety of intravitreal sirolimus for noninfectious uveitis of the posterior segment: results from the sirolimus study assessing double-masked uveitis treatment (SAKURA) program. Ophthalmology. 2020 Apr 3;S0161-6420(20)30317–1. 10.1016/j.ophtha.2020.03.033.
   Web of Science ®Google Scholar
• Mirshahi A, Namavari A, Djalilian A, et al. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behcet disease. Ocul Immunol Inflamm. 2009;17(1):59–64.
   PubMed Web of Science ®Google Scholar
• Ghassemi F, Mirak SA, Chams H, et al. Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection. J Ophthalmic Vis Res. 2017;12(1):44–52.
   PubMedGoogle Scholar